The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In particular, the mild restrictions that kept around 0.9 with the original virus strain would keep it around 1.3 (at least) if the new variants increase transmissibility of at least 40–50%, as reported in the literature49–51.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [50]
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Self-citationmRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557
Research works printed but not linked: 6
- Creech, SARS-CoV-2 vaccines., JAMA
- Logunov, 2021, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine., Lancet, 397, 671, 10.1016/S0140-6736(21)00234-8 · DOI · Paper page
- Shen? X, Tang? H, McDanal? C, . SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.? bioRxiv. Published online January 29, 2021. doi:10.1101/2021.01.27.428516? 33532764 · DOI
- Saad-Roy? CM, Morris? SE, Metcalf? CJE, . Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.? medRxiv. Published online February 3, 2021. doi:10.1101/2021.02.01.21250944? 33564785 · DOI
- Madhi? SA, Baillie? V, Cutland? CL, . Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa.? medRxiv. Published online February 12, 2021. doi:10.1101/2021.02.10.21251247 · DOI · Paper page
- Stamatatos? L, Czartoski? J, Wan? Y-H, . Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1.? medRxiv. Published online February 8, 2021. doi:10.1101/2021.02.05.21251182 · DOI · Paper page
Cited by
Sorted by citations
Giordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01334-5 · Cited by 192
Metadata
- Authors
- Moore, J. P.
- Affiliations
- Cornell University (US)
- Corresponding author
- Moore, John P.
- ORCID
- Moore, John P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-04-06
- Volume
- 325
- Issue
- 13
- Pages
- 1251
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3134901459
- Cited by
- 60
- References
- 5
- Citations by year
- 2024: 1 · 2023: 8 · 2022: 16 · 2021: 35
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- COVID-19 vaccines, vaccine allocation, vaccine prioritization, vaccination strategies, SARS-CoV-2
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Mass Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. https://app.cochat.ai/papers/10.1001/jama.2021.3465
- The paper
- Moore, J. P. (2021). Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. JAMA. https://doi.org/10.1001/jama.2021.3465
